Clinical cases presented here reinforce the hypothesis that GcMaf could become part of anticancer immunotherapeutic regimes.

Abstract Title:

GC protein-derived macrophage-activating factor decreasesα-N-acetylgalactosaminidase levels in advanced cancer patients.

Abstract Source:

Oncoimmunology. 2013 Aug 1 ;2(8):e25769. Epub 2013 Jul 29. PMID: 24179708

Abstract Author(s):

Lynda Thyer, Emma Ward, Rodney Smith, Jacopo Jv Branca, Gabriele Morucci, Massimo Gulisano,  Robert Eslinger, Stefania Pacini

Article Affiliation:

Lynda Thyer

Abstract:

α-N-acetylgalactosaminidase (nagalase) accumulates in the serum of cancer patients and its activity correlates with tumor burden, aggressiveness and clinical disease progression. The administration of GC protein-derived macrophage-activating factor (GcMAF) to cancer patients with elevated levels ofnagalase has been associated with a decrease of serum nagalase activity and with significant clinical benefits. Here, we report the results of the administration of GcMAF to a heterogeneous cohort of patients with histologically diverse, advanced neoplasms, generally considered as”incurable”diseases. In most cases, GcMAF therapy was initiated at late stages of tumor progression. As this is an open-label, non-controlled, retrospective analysis, caution must be employed when establishing cause-effect relationships between the administration GcMAF and disease outcome. However, the response to GcMAF was generally robust and some trends emerged. All patients (n = 20) presented with elevated serum nagalase activity, well above normal values. All patients but one showed a significant decrease of serum nagalase activity upon weekly GcMAF injections. Decreased nagalase activity was associated with improved clinical conditions and no adverse side effects were reported. The observations reported here confirm and extend previous results and pave the way to further studies aimed at assessing the precise role and indications for GcMAF-based anticancer immunotherapy.

Please see this article for a real life story of how Immunotherapy Bulgarian GcMAF works for even the rarest types of cancer.
Study Type : Human Study
Additional Links Nagalase explained: https://healingoracle.ch/2015/06/01/nagalase-in-blood
We do the research you do decide,
Love and Light
The Healing Oracle
Article Posted By: The Healing Oracle Team

Please join MD Fermín Celma Simón’s Facebook group for more open and unrestricted views and discussions on health:
The Naked Doctor reveals all. The white coat is off

Expertido


Join our growing numbers on MeWe: Healing Oracle
See the latest stories and news about GcMAF on our GcMAF Group
Also join us on Twitter | YouTube


Global Petition

Please sign our global petition against enforced vaccinations The intention of this petition is to present 5 million signatures to each President, Prime Minister, Health Minister and heads of state worldwide.
Vaccines are a global problem and need to be tackled on a global level.
If we stand as one, we have a chance of saving the children of the future.

Keep Us Advertising Free

Healing Oracle is made possible by the support of its readers. If you find the posts and resources useful, please consider making a contribution to support us (in any amount) so we can continue to inform and assist people around the world. We feel that giving a voice to those who have transformed their health, or that of a loved one, with alternative treatment is an important mission. Thank you for valuing our work and helping it to continue.

Donate. Should you choose to kindly donate towards our time and efforts, please use the ‘donations’ box above on the top right hand side (on Desktop), or the donations box below (on Mobile)

About the Author

The Healing Oracle Team
About Healing Oracle

The Healing Oracle team is made up of a group of unpaid volunteers. Collectively we share the same interests and goals and comprise of decades of medical and holistic experience. 

Our mission is to spread our knowledge and experience of the medical world, from both sides of the so called divide between holistic and mainstream practices. There is good and bad on both sides and we hope to unite the best of both worlds.

Please read our philosophy, here in this article from MD Fermin Celma

Be the first to comment on "Clinical cases presented here reinforce the hypothesis that GcMaf could become part of anticancer immunotherapeutic regimes."

Leave a comment